Urologix to Host Its Fiscal Year 2014 Third Quarter Conference Call
30 Abril 2014 - 6:00PM
Urologix®, Inc. (OTCQB:ULGX) will host a conference call to present
fiscal year 2014 third quarter results on Tuesday, May 6, 2014 at
4:00 p.m. CT, following the Company's post-market press release on
the same day. On the day of the call, please dial 1--866-515-2911
and enter the Participant Passcode 73790575 at least 10 minutes
prior to the call. The conference call will be broadcast live over
the Internet at www.urologix.com. Greg Fluet, Chief Executive
Officer, will host the call.
Webcast listeners should log on at least 10 minutes prior to the
scheduled start time of the call to register and download or
install any required audio software. A replay of the call will be
available until May 13, 2014 at 11:59 p.m. CT. To listen to the
replay, please dial 1--888-286-8010 and enter the Participant
Passcode 27765568.
The webcast is also being distributed over CCBN's Investor
Distribution Network to both institutional and individual
investors. Individual investors can listen to the call through
CCBN's individual investor center at www.companyboardroom.com or by
visiting any of the investor sites in CCBN's Individual Investor
Network. Institutional investors can access the call via CCBN's
password-protected event management site, StreetEvents
(www.streetevents.com).
About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures,
markets and distributes minimally invasive medical products for the
treatment of obstruction and symptoms due to Benign Prostatic
Hyperplasia (BPH). Urologix' Cooled ThermoTherapy™ produces
targeted microwave energy combined with a unique cooling mechanism
to protect healthy tissue and enhance patient comfort. The
Cooled ThermoTherapy™ product line includes the CoolWave® and
Targis® Control Units and the CTC Advance® and Targis® catheter
families. The Prostiva® RF Therapy System delivers radio
frequency energy directly into the prostate destroying prostate
tissue, reducing constriction of the urethra, and thereby relieving
BPH voiding symptoms. Both of these products provide safe,
effective and lasting relief of the symptoms and obstruction due to
BPH. Prostiva® is a registered trademark of Medtronic, Inc., used
under license. All other trademarks are the property of
Urologix.
CONTACT: Brian Smrdel
Chief Financial Officer
Urologix, Inc.
763-475-1400
bsmrdel@urologix.com
Urologix (CE) (USOTC:ULGX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Urologix (CE) (USOTC:ULGX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Urologix Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de